The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|May 15, 2021
- Pharmaceutical Technology-05-15-2021
- Volume 2021 eBook
- Issue 2
Using ddPCR to Detect Mycoplasma Contamination
Author(s)Mark White
The sensitivity of droplet digital PCR helps manufacturers detect Mycoplasma contamination in AAV-based gene therapy products.
Advertisement
The accelerated pace of gene therapies is a sign of enhancements in our understanding of genetics and viral engineering as well as innovation in manufacturing processes. Despite this progress, gene therapy development is not a perfect science, and manufacturers must be careful to monitor the quality of their products before they reach patients. The sensitivity of droplet digital PCR (ddPCR) helps manufacturers detect Mycoplasma contamination in adeno-associated vector-based gene therapy products.
About the author
Mark White, PhD, is associate director, Biopharma Product Marketing, at Bio-Rad Laboratories.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing,May 2021
May 2021
Pages: 26–32
Citations
When referring to this article, please cite it as M. White, “Using ddPCR to Detect Mycoplasma Contamination," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2021).
Articles in this issue
over 5 years ago
Sterile Filtration: Reducing Risk, Ensuring Safetyover 5 years ago
Filling Small Batchesover 5 years ago
Breaking the Cold Chain for Vaccinesover 5 years ago
The Impact of COVID-19 on Biologics Regulationsover 5 years ago
Packaging Biologic Drugs for Clinical Trialsover 5 years ago
Tracking Technologies Guard Vaccine Cold Chainover 5 years ago
Eyeing Up Success in Fill/Finishover 5 years ago
Reducing Packaging Costs for Prefilled Syringesover 5 years ago
Biologics Facilities Expand and Establish New Locations in 2021Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement